Physician profile
Jeffrey Alan Olson
NPI 1629047907
$11,611.68
in general payments reported to CMS, 2019-2025
9 companies · $2,516 in 2025
The $2,516 reported for 2025 was less than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $756 · 2020: $1,582 · 2021: $1,396 · 2022: $1,330 · 2023: $2,790 · 2024: $1,241 · 2025: $2,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,617 · Travel and Lodging: $930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,617.48 |
| Travel and Lodging | $929.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $5,140.35 | 2019-2025 | Rhythmia Mapping System, Watchman Access System, General - Therapies |
| Abbott Laboratories | $3,414.37 | 2019-2025 | Ensite Precision, Ensite, Quadra Assura |
| Medtronic, INC. | $1,675.60 | 2021-2025 | Micra, Affera Mapping System, Aurora Ev-Icd Mri Surescan |
| Biotronik INC. | $438.77 | 2024-2025 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Biosense Webster, INC. | $367.83 | 2023-2025 | Carto 3, Nuvision Ice Catheter |
| Medtronic Vascular, INC. | $320.62 | 2019-2020 | |
| Atricure, INC. | $153.86 | 2021-2023 | |
| Cardiva Medical, INC. | $83.43 | 2024-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f, Cardiva Vascade Mvp Vvcs 6-12f |
| Novartis Pharmaceuticals Corporation | $16.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Olson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.